Cardiology-focused Investigators from University Hospital Galway complete a first-in-man clinical trial for a sensor that may help patients with heart failure stay out of the hospital. The investigational product, known as the Cordella Sensor from U.S.-based company called Endotronix, detects changes in the health of patients with heart failure while securely transmitting information to the cardiovascular team. With this data in real time, the cardiovascular team can not only receive relevant updates but also can intervene with the goal of preventing heart failure flare-up resulting in emergency hospitalization.
Timely Intervention for Heart Failure
With the advent of the COVID-19 pandemic and associated movement restrictions and lockdowns, this investigational technology may be of particular importance when patient’s movement is restricted to prevent contact with SARS-CoV-2, the virus behind the COVID-19 pandemic, as reported by the Saolta University Health Care Group.
Track Record thus Far
The Western Ireland-based hospital has treated seven advanced heart failure patients to date: implanting the Cordella Sensor in their right pulmonary artery to monitor their heart pressure during the past 18 months.
Enabling Remote Cardiovascular Care Monitoring & Care Coordination
The Cordella Sensor uses a secure cloud-based system to enable the clinical team located in the hospital to read the physiological data captured by the sensor. In this way, the patient can be safe at home while the hospital team can not only monitor and identify any material changes in the patients’ condition but also modify their medication and make other timely care decisions.